A high number of preclinical studies have demonstrated the ability of Src inhibitors like dasatinib to inhibit most of these drug target genes, as PDGFRa, PDGFRb or FYN, and to overcome chemoresistance in CRC [60,61,62,63,64,65,66,67]. This evidence concerns the gene PDGFRA and colorectal carcinoma.